In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. - Wikidata - wikimedia - TriplyDB

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

http://www.wikidata.org/entity/Q35103227

about

Cytomegalovirus antivirals and development of improved animal models Current and potential treatments for ubiquitous but neglected herpesvirus infections Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus Antiviral drug resistance of human cytomegalovirus.Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27 Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers.In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults Rhesus cytomegalovirus is similar to human cytomegalovirus in susceptibility to benzimidazole nucleosides Progress in the development of new therapies for herpesvirus infections Antiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoesters Development of new antivirals for herpesviruses.Antivirals and antiviral strategies.Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy.Epidemiology, pathogenesis and prevention of congenital cytomegalovirus infection.Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication.Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene.Update on new antivirals under development for the treatment of double-stranded DNA virus infections Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus.Conserved herpesvirus protein kinases.Human cytomegalovirus UL97 kinase alters the accumulation of CDK1.Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes.Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses A herpes simplex virus scaffold peptide that binds the portal vertex inhibits early steps in viral replication.Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir Maribavir: a novel antiviral agent with activity against cytomegalovirus.Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir.Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir.Human herpesvirus 6 infections after liver transplantation In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections.Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication.Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections.The search for new therapies for human cytomegalovirus infections.Recent developments in the prevention and treatment of Epstein-Barr virus-associated lymphoproliferative diseases.Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.Comparison of effects of inhibitors of viral and cellular protein kinases on human cytomegalovirus disruption of nuclear lamina and nuclear egress.

P2860

Q27000998-0CDBE468-7EB2-41A2-8B9F-8E81529DE451 Q27023452-9BF15ECE-8513-480D-A5EF-4C489BF7C6A6 Q28552095-C06669EA-0C28-4A30-8989-FAFBD91F87AD Q30430427-137EC11F-EAED-47CA-899F-910907D7F8DD Q31011523-4685C2CA-5554-4B7D-B6DE-FC38EE534BBF Q33227757-EE4C1452-8C75-48A3-B217-FF7A0E775AE2 Q33815957-29E2A2E8-3EDD-435E-89F1-6472AA2535AE Q33857275-4EF9485F-2FA5-474C-943F-3DBDA8E0247A Q33935329-FE69309A-6F3C-497F-A1BF-0AEE2928592F Q34510611-7CFA9ECC-858D-4247-83D1-335962E4D9BD Q35124909-8340E140-E81C-4AA7-BB8B-328F11CADA39 Q35590695-502016EE-BD1B-4561-AE19-AACF29DD0CA3 Q35636006-1D073E13-E77A-4F6B-BDD1-59B8032C0464 Q35669533-E8B4B0E5-553D-4277-8394-70BBDCBCCC09 Q35889586-B7EA2842-3192-4DA9-AF93-8D3D3D8F8C8E Q35917421-3126540C-045A-40FC-9F60-DD15E21C83E0 Q35964751-12D6E594-3ECD-491F-B762-35D0657F5445 Q36086432-8120BCBE-FB77-41E3-9799-1BBB3135C569 Q36172394-C113748A-A842-4429-9071-8707EF9816AC Q36185647-0D8C47B2-4298-4D9B-9B7A-E8074BEA5D7E Q36442795-9BE05117-7DCA-4D26-9144-D5DFF4009A41 Q36491044-E8317A69-576B-4EC4-A940-93B762849CF9 Q36523126-4464A44E-8F24-46D5-8843-D4F988BCD322 Q36594113-5279EAED-AC3D-4D44-8D99-3C99886572E1 Q36759709-6C492D34-977B-4E73-AB37-63D9CBB8CFB9 Q36911715-695F7D47-8A85-4519-AF23-F106AB7AA4A4 Q37085793-0FCE0D15-ADDD-4D12-A774-AE030658DF5B Q37242251-7022C2B8-AAC8-4277-BA20-F6FA92256B87 Q37278489-846D402F-D2AE-4E6F-808E-F4C6C3A579B5 Q37453329-104AC43F-8D18-4E62-9870-597D90F53A70 Q37478310-1BB9E7C7-4949-44F1-B94B-1D4490085F02 Q37507814-CDE868BF-0A1A-492F-BEB1-8C7EA6F43C55 Q37544751-97C0368D-9AA1-48C5-A338-546D364C7247 Q37624896-5E82A7EC-3EED-4D87-8D36-45ED3A41625A Q37734377-0F39994F-1D83-4008-B21A-53966E278A48 Q37734561-D2FC8D72-01D8-4D36-91B0-A12A4116FA35 Q37811458-F0F46890-2A27-46A0-8486-56853CEA78BE Q37906623-6AAF3CC6-6B26-4F0A-B83B-59E2386BED72 Q38032320-55347401-FA05-4C61-9554-6B9B70B1B5B7 Q38981231-73D8A740-903E-4C55-BB89-348C030F9B99

P2860

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

http://www.wikidata.org/entity/Q35103227

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

@ast

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

@en

type

label

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

@ast

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

@en

prefLabel

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

@ast

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

@en

P1433

Q35103227-910EFBE0-02F0-427A-9C42-B34E998BE4C1

P1476

Q35103227-67610A76-E5ED-4257-B109-AB5FA28CD844

P2093

Q35103227-0823E141-06EF-4D6E-852F-D6CD60AF49D5

Q35103227-0D190733-732D-4B59-AF00-76785D1DE8CE

Q35103227-198BA640-C053-41A0-829F-B1B220EE02C3

Q35103227-397390BF-C773-45DC-AEF4-38870B11F681

Q35103227-423872ED-552F-4058-B9FF-31CD26A7402D

Q35103227-51DAE8AA-0964-4F49-A64D-C67B7C3F2F13

Q35103227-7F135DD3-3F9C-497D-9428-DAA1234DB10C

Q35103227-A440E8ED-572A-4C5E-A679-E0EBAF1BE044

Q35103227-AF52D063-2D36-4F36-84F6-A9E680561DC0

Q35103227-C4F596B6-80A5-4E41-8BD2-364264546F2C

P2860

Q35103227-07CE2BB1-1D35-4E91-9FD3-E65D89F7494A

Q35103227-12AE2240-563D-4496-A83E-2D41AC6DE021

Q35103227-135FC72B-3725-451D-8347-0E34087B8CE1

Q35103227-19F4D9DC-8791-4926-8874-80E4B6AC21BD

Q35103227-302AF725-6A73-4129-9884-9F31C1769C00

Q35103227-304781E7-334D-4D2E-B86E-D6FC62843D7C

Q35103227-4594E025-483C-47FA-8766-ABF12FFA91E6

Q35103227-46B72483-8FD6-4C1B-B2D5-0A8DA9B122D2

Q35103227-52E063A2-A01C-4EFB-86BD-CD5940307AA1

Q35103227-58849CF0-730F-4033-9C09-446BC97A0D00

P304

Q35103227-38EE0ACF-BC57-4A34-A0DA-6A8DD0479D0C

P31

Q35103227-2E3998EB-B9DB-483A-BB52-26AD1672A286

P356

Q35103227-62961BA9-DCE8-4726-8E68-CCC42A261F79

P407

Q35103227-4CD01DFE-3CC0-4936-BBA7-885DFDD2463B

P433

Q35103227-E980BFAB-78E2-4E39-B78A-4F2B0C8B7BDC

P478

Q35103227-1DC2F23E-1BA0-4EFB-B259-2FDB3CE919AA

P577

Q35103227-C1E1B120-B88F-4900-A776-11557C0990A6

P698

Q35103227-7F58A11F-3CE3-49D2-88D3-A4F7716FF873

P932

Q35103227-B1C2D45E-891C-48F4-81B2-F15E3559DB03

P356

AAC.47.7.2186-2192.2003

P1433

Antimicrobial Agents and Chemotherapy

P1476

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

@en

P2093

Caroll B Hartline

http://www.w3.org/2001/XMLSchema#string

Deborah J Bidanset

http://www.w3.org/2001/XMLSchema#string

Earl R Kern

http://www.w3.org/2001/XMLSchema#string

Emma A Harden

http://www.w3.org/2001/XMLSchema#string

John C Drach

http://www.w3.org/2001/XMLSchema#string

Karen K Biron

http://www.w3.org/2001/XMLSchema#string

Leroy B Townsend

http://www.w3.org/2001/XMLSchema#string

Mark R Underwood

http://www.w3.org/2001/XMLSchema#string

Nicole L Kushner

http://www.w3.org/2001/XMLSchema#string

Stephanie L Williams

http://www.w3.org/2001/XMLSchema#string

P2860

Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis

Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.

In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections

Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94

Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease

Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product

Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56

Synthesis and antiviral evaluation of halogenated beta-D- and -L-erythrofuranosylbenzimidazoles.

Valganciclovir.

P304

2186-2192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.47.7.2186-2192.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12821466

http://www.w3.org/2001/XMLSchema#string

P932

161863

http://www.w3.org/2001/XMLSchema#string